Controlled release and bioactivity of the monoclonal antibody rituximab from a porous matrix: A potential in situ therapeutic device

S. Simovic, K. R. Diener, A. Bachhuka, K. Kant, D. Losic, J. D. Hayball, M. P. Brownc, K. Vasilev

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)

Abstract

We report on a platform for extended release of biologically-active therapeutic antibodies. Extended antibody release has been achieved by utilising a plasma polymer film of controlled and predetermined thickness deposited on the top of a porous platform loaded with rituximab. Antibody release kinetics directly correlates to the plasma polymer film thickness that is in turn controlled by the plasma polymer deposition time. After 1 month, 82%, 60% and 45% of the antibody is released from platforms coated with plasma polymer for 50 s, 150 s and 300 s, respectively. Activity of the released antibody was assessed in cultures of CD20-positive Daudi cells by using polyacrylamide gel electrophoresis and flow cytometry. The results from gel electrophoresis and flow cytometry indicate that the antibody had maintained its integrity during the release process. This work provides a proof-of-concept technology that achieves extended release of biologically active rituximab for more than 30 days.

Original languageEnglish
Pages (from-to)210-214
Number of pages5
JournalMaterials Letters
Volume130
DOIs
Publication statusPublished - 1 Sept 2014
Externally publishedYes

Bibliographical note

Funding Information:
KV thanks to ARC for support through fellowship FT100100292 .

Keywords

  • Cancer therapy
  • Drug release
  • Implant
  • Plasma polymerization

Fingerprint

Dive into the research topics of 'Controlled release and bioactivity of the monoclonal antibody rituximab from a porous matrix: A potential in situ therapeutic device'. Together they form a unique fingerprint.

Cite this